Research team one step closer to finding cure for liver disease
A team of researchers is one step closer to developing a remedy for a severe form of non-alcoholic fatty liver disease that is currently untreatable.
The researchers have found that deactivating a protein called interleukin-11 (IL-11) with human antibodies reverses inflammation and scarring of the liver in patients suffering from non-alcoholic steatohepatitis, the leading reason for liver transplant worldwide.
This stage of the disease is marked by liver inflammation and scar tissue caused by a build-up of fat in the liver and can lead to liver failure and cancer.
One in three people here has non-alcoholic fatty liver disease, even if they are not obese.
Duke-NUS Medical School, National Heart Centre Singapore and biotechnology company Enleofen Bio collaborated on the study.
The team found that the IL-11 protein - contrary to previous research - causes fibrosis and organ damage.
It triggers the development of non-alcoholic steatohepatitis and fat accumulates in the liver of patients.
The protein is most common in people who are obese and diabetic and causes fatigue, abdominal pain, itchy skin and nausea.
Antibodies developed by the researchers inhibited the protein in mice, which were placed on a high-fat, high-sugar diet for six months.
After the mice were put on the antibodies for eight weeks, the liver damage, inflammation and fibrosis were reversed by half, and they also had lower blood levels of cholesterol and glucose, said Dr Anissa Widjaja, a senior research fellow at Duke-NUS' Cardiovascular and Metabolic Disorders (CVMD) Programme and first author of the study.
The findings were published in the Gastroenterology journal this month.
There have been multiple recent failures of drugs in clinical trials, said Professor Stuart Cook, director of the CVMD Programme.
The researchers also believe that the antibodies can repair scarring caused by fibrosis in other parts of the body.
Enleofen Bio is developing the drug and aims to have it ready for clinical trials by the end of next year.